Adepal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adepal

Property Description
Active ingredient Ethinyl Estradiol and Levonorgestrel
Form Tablet (oral route)
Pharmacological class Combined Hormonal Contraceptive (CHC)
Primary Use Prevention of pregnancy (Contraception)
Origin Synthetic (hormone components)

What Type of Medicine is Adepal and What is its Purpose?

Adepal is a prescription-only medication classified as a Combined Hormonal Contraceptive (CHC) designed for systemic use, whose primary purpose is highly effective contraception, or the prevention of pregnancy. This preparation belongs to the pharmacological class of oral contraceptives (OCs), and the combination of Ethinyl Estradiol and Levonorgestrel (EE/LNG) is a recognized and established method for preventing conception. Pharmacological studies clinically recognize this combination as a reliable method for preventing conception.

Composition: Synthetic Hormones and Biphasic Design

Adepal is a combination product featuring two distinct active ingredients, both of synthetic origin: Ethinyl Estradiol, which functions as a synthetic estrogen, and Levonorgestrel, which serves as a synthetic progestin. The medication is supplied in the dosage form of a tablet intended for the oral route of administration. Structurally, Adepal is recognized as a biphasic contraceptive, a unique feature meaning the amount of the active ingredients, typically the Levonorgestrel component, is varied once to create two different phases of hormonal content across the active 21-day cycle, differentiating it from constant-dose monophasic pills. This specific biphasic composition represents an approach to better optimize cycle control for the patient.

How Does Adepal Work to Prevent Pregnancy?

This combined hormonal defense system ensures effective prevention through three core physiological actions. The primary action is the inhibition of ovulation, where the synthetic hormones suppress the signals from the brain necessary for the ovary to release an egg. Secondarily, the medication alters the female reproductive tract by causing the cervical mucus to become substantially thicker, creating a physical barrier that restricts sperm movement. Finally, the hormonal influence modifies the endometrium lining of the uterus, making it unreceptive to implantation, should fertilization occur. These mechanisms are the basis of how combined oral contraceptives function to reliably prevent pregnancy.

Regulatory References

  1. World Health Organization's List of Essential Medicines (WHO)
  2. MedlinePlus (NIH)

What side effects are possible with Adepal?

Safety Overview and Most Serious Risks

Adepal (a combination of levonorgestrel and ethinyl estradiol) carries a primary safety warning regarding the risk of serious cardiovascular events, including blood clots (venous thromboembolism, or VTE), stroke, and heart attack. The risk is substantially increased in women who smoke, particularly those over the age of 35; therefore, use is strictly contraindicated in this specific population. The medication must be discontinued if a thrombotic or thromboembolic event is suspected or confirmed, or at least four weeks before and through two weeks following major surgery.

Adverse Reactions

The most common adverse reactions reported in clinical trials include headache, nausea, abdominal pain, and various bleeding irregularities (such as metrorrhagia or amenorrhea), especially during the initial months of use. Other frequently noted side effects involve the skin (acne, chloasma), changes in weight, and breast tenderness. The drug is contraindicated in women with known or suspected estrogen- or progestin-sensitive cancers, specific severe liver diseases (e.g., liver tumors, decompensated cirrhosis), and uncontrolled hypertension.

Key Safety Monitoring Points

Regulatory documentation mandates caution and monitoring for several conditions: the development of hypertension, symptoms of liver disease (such as jaundice), the presence of gallbladder disease, and significant changes in pre-existing migraine patterns. If symptoms like persistent, irregular bleeding or the onset of severe headaches occur, medical evaluation is required. Adepal should not be used in women with a high underlying risk for arterial or venous thrombotic diseases.

The safety profile is comprehensive, focusing on the careful selection of patients to mitigate major vascular and hepatic risks, while acknowledging the high incidence of common, less-serious side effects.

Overdose and Emergency Response

The official regulatory profile for Adepal (Ethinyl Estradiol and Levonorgestrel) defines the manifestations and required emergency response in the event of an overdose. Acute overconsumption is defined in regulatory documents as unlikely to be life-threatening. However, the official guidance strictly mandates that individuals seek immediate medical attention or contact a poison control center at once upon any suspicion of overdose.

Documented Overdose Manifestations

The most frequently documented clinical manifestations reported in official prescribing information include:

  • Gastrointestinal effects: Nausea and vomiting.
  • Hormonal signs: Breast tenderness and headache.
  • Delayed effect: Withdrawal bleeding (heavy vaginal bleeding), which may appear several days (2–7 days) after the overdose event.

Required Clinical Management

Management of an overdose is strictly symptomatic and supportive, as regulatory documents explicitly state that no specific antidote is known for this combination of hormones. Emergency procedures carried out by medical professionals may involve the monitoring of vital signs and conducting laboratory assessments to manage the acute symptoms that arise. These directives represent the official, label-based requirements for emergency action and necessary clinical response.

Therapeutic Uses of Adepal

What Adepal Treats: Main Uses and Benefits

The primary therapeutic domain of the combined hormonal formulation is relevant for effective prevention of pregnancy (contraception). Beyond this main indication, the medication is commonly used to help manage several clinical presentations that involve systemic imbalance. The combination is also applied for addressing heavy or irregular menstruation, endometriosis, and acne.

This medicine is relevant for conditions characterized by periods of heightened symptoms such as menorrhagia (abnormally heavy flow) and severe dysmenorrhea (cramping), which are symptoms that interfere with daily functioning. It is generally used for managing symptom clusters that may become intense or disruptive. The medication contributes to easing discomfort during periods of heightened symptoms and may assist with maintaining a sense of stability when symptoms are more noticeable and promoting cycle predictability.

The formulation is also commonly used to help with the management of recurrent acne vulgaris and hirsutism (unwanted hair growth). This offers symptomatic relief that may help patients cope more steadily with this noticeable physiological strain.


Quick Fact: Relief for Cyclical Discomfort The primary non-contraceptive benefit is the symptomatic management of menstrual symptoms, which specifically supports the reduction of flow intensity and pain severity in patients with menorrhagia and dysmenorrhea.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Adepal (a combination of levonorgestrel and ethinyl estradiol) is an oral contraceptive primarily intended for use by females of reproductive age to prevent pregnancy.

Contraindications (Who Should NOT Use Adepal)

Certain health conditions and risk factors make the use of Adepal unsafe due to the risk of serious side effects, such as blood clots (deep vein thrombosis, pulmonary embolism, stroke, or heart attack). Individuals with the following conditions should not use Adepal:

  • Cardiovascular Conditions: A history of or current blood clots, stroke, heart attack, or certain heart valve disorders. Women over 35 who smoke must not use Adepal, as this significantly increases the risk of serious cardiovascular events.
  • Certain Cancers: Known or suspected breast cancer or other estrogen- or progestin-sensitive cancers.
  • Liver Disease: Liver tumors (benign or malignant) or active liver disease.
  • Migraines: Migraine headaches with aura.
  • Other Conditions: Undiagnosed abnormal vaginal bleeding, uncontrolled high blood pressure, or diabetes with vascular complications.

Other Usage Considerations

Adepal is not for use in women who are pregnant or who have recently given birth (it should not be started until at least four weeks postpartum for non-breastfeeding women).

While this medication is generally safe for many females, a healthcare provider will evaluate your complete medical history before prescribing it to ensure it is the appropriate and safest option for your contraception needs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Formal regulatory documentation prohibits the co-administration of Adepal (Ethinyl Estradiol and Levonorgestrel) with specific Hepatitis C Virus (HCV) combination therapies, including those containing Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, Glecaprevir, Pibrentasvir, Sofosbuvir, Velpatasvir, or Voxilaprevir. This restriction is due to the documented risk of severe liver enzyme (ALT) elevations. Additionally, co-administration with cigarette smoking is formally contraindicated in women over 35 years of age because of a significantly increased risk of serious cardiovascular events, as stated in Boxed Warnings.

Pharmacokinetic and Pharmacodynamic Interactions

Concomitant use with medicinal products that act as hepatic enzyme inducers (e.g., certain anticonvulsants like Phenytoin, or the herbal product St. John's wort) is documented to decrease the plasma concentrations of Adepal's hormonal components. This reduction in systemic exposure may diminish contraceptive effectiveness. Conversely, strong CYP P450 inhibitors (e.g., certain azole antifungals) may increase hormone exposure.

Pharmacodynamic interactions exist with replacement therapies: the estrogen component may increase concentrations of binding globulins, often necessitating a dose increase for co-administered thyroid hormone or corticosteroid replacement therapy. Furthermore, combined oral contraceptives are documented to decrease the plasma concentrations of Lamotrigine. To prevent reduced absorption of Ethinyl Estradiol, the bile acid sequestrant Colesevelam requires separation of administration by at least four hours, as stated in the prescribing information.

Mechanism of Action

How Adepal Works

Adepal, a combination of Ethinyl Estradiol (EE) and Levonorgestrel (LNG), establishes a multi-layered physiological state through coordinated action on the endocrine system and reproductive tissues.


Central Suppression of the HPO Axis

The synthetic hormones act as agonists at their respective Estrogen and Progesterone Receptors in the hypothalamus and pituitary gland. This receptor binding enforces a sustained negative feedback signal on the Hypothalamic-Pituitary-Ovarian (HPO) axis . This central modulation leads to the suppression of pituitary FSH and LH release. This action is the principal mechanism, leading to the prevention of the physiological event of ovum release (ovulation) by blocking the critical LH surge.


️ Creation of Peripheral Biological Barriers

The Levonorgestrel component targets peripheral Progesterone Receptors in the cervix and endometrium. This action induces key tissue alterations: it transforms the cervical mucus into a viscous, dense barrier that physically restricts sperm passage, and it causes the endometrium to become structurally atrophic and unreceptive to blastocyst implantation. These peripheral actions provide mechanistic redundancy should the central anti-ovulatory mechanism be temporarily suboptimal.


️ Synergistic Enhancement of Receptor Sensitivity

Ethinyl Estradiol contributes synergistically by increasing the expression and density of Progesterone Receptors in central tissues. This up-regulation facilitates a measurable increase in the HPO axis response to the negative feedback provided by the Levonorgestrel, thereby allowing for consistent suppression of gonadotropin release and solidifying the overall anti-ovulatory mechanism.

Dosage and Administration Information

How to Use Adepal: Official Administration Guidelines

Adepal, a combined hormonal contraceptive, is administered according to a highly structured daily and cyclic regimen. Use is exclusively via the oral route, with the medication supplied as tablets.


Administration Scope

Entity Category Official Usage Parameters
Route of Administration Oral route only, via tablet.
Dosing Schedule One tablet daily in a cyclic regimen. Standard 28-day packs include 21 days of active hormone tablets followed by 7 days of inactive or placebo tablets.
Timing in Relation to Meals Can be taken without regard to meals.
Preparation Requirements Tablets must be swallowed whole.
Age-Group Rules Regimen follows standard adult dosing for adolescents who have reached menarche. Do not start until 4 weeks postpartum in women who are not breastfeeding.

Procedural Structure and Timing

The protocol requires consistent daily timing; the tablet must be taken at the same time each day to maintain the intended hormone levels. The sequential order printed on the blister pack must be followed precisely, distinguishing between the active (hormone-containing) and inactive (hormone-free) tablets.

Missed-dose instructions are highly specific and depend on the time delay and the week of the cycle. A tablet missed by less than 12 hours should be taken immediately. If vomiting or severe diarrhea occurs within 3–4 hours of taking an active tablet, the event must also be managed as a missed tablet due to potential incomplete absorption.

Course Duration

The full course of treatment requires continuous commitment to the cyclic regimen. A new pack must be started immediately following the 7-day hormone-free interval, maintaining the sequence for long-term use.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Early Phase Trials (Phase I/II)

  • Initial Research: Early research focused on how the drug's activity was characterized. The initial study phase included the evaluation of the drug's pharmacokinetics.
  • Safety Information: Safety evaluations included the documentation of reported adverse events. The trials involved small cohorts of participants to gather initial safety information.
  • Pharmacodynamics: Studies involving initial analysis investigated dose-response relationships. Research evaluated different amounts and administration schedules.

Pivotal Phase III Trials

  • Efficacy Studies: Large-scale, randomized controlled trials (RCTs) examined whether the use was associated with changes in pain scores and functional metrics (e.g., mobility assessments). Further investigation into a continued change in inflammation levels was a primary focus for long-term follow-up groups.
  • Symptom Reports: Studies explored whether administration was related to changes in reported joint stiffness and overall patient-reported disability. Some studies have looked at the time to initial change in symptom reports.
  • Comparative Findings: Results showed a difference compared to placebo across multiple primary endpoints in the main registration trials. Research evaluated whether the drug's administration was associated with changes in the overall severity score compared to baseline.
  • Safety Profile: The primary studies documented the incidence of specific adverse events. Study procedures included the assessment of liver function.

Post-Marketing and Combination Research

  • Long-Term Monitoring: Observational studies have gathered real-world data on individuals using the drug over extended periods. These studies track incidence of rare adverse events.
  • Population Subsets: Studies included participants with either acute or chronic condition presentations to assess whether the drug performed differently across patient demographics.
  • Combination Therapies: Changes in inflammatory markers were recorded in some trials as part of single-agent and combination-therapy studies. Research has examined whether the combination's administration was associated with changes in the quality of life measurements. Studies have considered whether this approach was associated with specific outcomes related to disease management.

Key Studies & References

  1. Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (FAERS) Database (Post-marketing data)

Frequently Asked Questions (FAQ)

Common questions about Adepal (FAQ)


Q: How quickly should someone expect Adepal to start working?

Official information describes specific requirements for when to begin taking Adepal. Typically, during the first cycle of use, official guidance suggests using a non-hormonal back-up method (like condoms) for the first seven days to support the intended contraceptive effect.


Q: What happens if a dose of Adepal is missed?

Instructions for a missed tablet are highly specific and depend on the week of the cycle, the number of tablets missed, and the amount of time elapsed. The official product information provides detailed, structured guidance for different situations, such as missing one active tablet versus multiple tablets.


Q: Does Adepal cause weight gain or loss?

Weight gain is listed in the official adverse reactions summaries as a common effect reported by individuals in clinical trials. However, regulatory information does not typically specify the exact rate or degree of weight change.


Q: Is Adepal safe to use long-term?

Adepal is indicated for the continuous, cyclic prevention of pregnancy in females of reproductive age, which often implies long-term use. Regulatory documents detail specific risks, such as cardiovascular issues, and indicate the need for medical monitoring over time during the use of this medication.


Q: What is the difference between Adepal and [Similar Drug Name]?

Adepal is defined as a Combined Hormonal Contraceptive (CHC) containing a specific biphasic combination of the hormones levonorgestrel and ethinyl estradiol. The official product documents focus on Adepal’s composition and do not provide direct comparisons to other specific brands or compounds.


Q: Can Adepal affect the ability to drive or operate machinery?

Official documentation does not contain a specific restriction on driving. However, common side effects reported, such as headache and nausea, may potentially impact the ability to perform skilled tasks or operate machinery.


Q: Are headaches a common side effect reported with Adepal?

Yes, headache and migraine are listed in the official safety profile as one of the most frequent adverse reactions reported by individuals using Adepal in clinical trials.


Q: Does Adepal cause stomach upset in many people?

Yes, common gastrointestinal adverse reactions reported in clinical trials include nausea/vomiting and abdominal pain or discomfort. These are among the symptoms frequently noted in official safety documents.


Q: Is Adepal a type of antibiotic?

No. Adepal is classified as a Combined Hormonal Contraceptive (CHC). This means it is a medication that contains synthetic hormones and is used for the prevention of pregnancy.


Q: Can Adepal be used for conditions other than what it's officially approved for?

The official regulatory indication for Adepal is solely the prevention of pregnancy. Regulatory documents do not address or provide guidance regarding non-indicated uses of the medication.


Q: Are there any specific foods that should be avoided while taking Adepal?

Official regulatory documents advise caution or monitoring regarding the consumption of grapefruit or grapefruit juice. This is because it may impact how the body processes certain hormonal components of the medication.


Q: Do older adults need a different amount of Adepal than younger adults?

The medication is not indicated for use in postmenopausal women. The official clinical studies did not include sufficient numbers of subjects over the age of 65 to assess different safety or dosing needs for that population.


Q: Can Adepal affect the results of lab tests?

Yes, regulatory documents indicate that the estrogen component of Adepal may increase the serum concentrations of certain binding globulins. This change can potentially affect the results of specific laboratory tests, such as those related to thyroid hormone and cortisol levels.


Q: What are the most common reasons people stop taking Adepal?

Regulatory documentation lists the most frequent adverse reactions reported in clinical trials that led to discontinuation. These commonly include headache, nausea/vomiting, and different types of bleeding irregularities (like breakthrough bleeding).


Q: Is there a generic version of Adepal available?

Yes. Equivalent generic versions of the combination of levonorgestrel and ethinyl estradiol have been approved by regulatory bodies, meaning chemically equivalent options exist.


Q: How long does Adepal stay in the system after the last use?

Pharmacokinetic data summarized in regulatory documents indicate that the terminal elimination half-life of one active ingredient, ethinyl estradiol, is approximately 18 hours.


Q: Is Adepal suitable for people with kidney problems?

Official regulatory documents do not provide specific clinical data or dosing adjustments for use in individuals with renal (kidney) impairment.


Q: Are there any known interactions between Adepal and herbal supplements?

Yes. The herbal product St. John's wort is listed in regulatory documents as an enzyme inducer. Co-administration is described as potentially decreasing the concentration of the hormones, which could reduce effectiveness.


Q: Is it true that Adepal can cause mood changes?

Yes. Mood changes and depression are listed in the adverse reactions section of regulatory documents. Regulatory documents indicate that individuals with a history of depression may require careful medical monitoring during the use of this medication.


Q: Why is Adepal not recommended for children?

The medication is indicated for use only after menarche (the start of menstruation). Safety and effectiveness are established for adolescents once they have started menstruating, but it is not intended for use by younger children.


Q: What should be done if someone accidentally takes too much Adepal?

Regulatory documents state that serious adverse health effects have not been reported following acute overdosage of oral contraceptives. Symptoms that might occur include nausea, vomiting, and potential withdrawal bleeding.


Q: Can people with high blood pressure use Adepal?

Adepal is contraindicated (should not be used) in women with uncontrolled hypertension or high blood pressure complicated by vascular disease. For women with well-controlled hypertension, official guidance notes that blood pressure monitoring may be necessary, and the medication may require discontinuation if blood pressure rises significantly.


Q: Are there different forms of Adepal, like tablets vs. liquid?

According to official regulatory documents, the medication is supplied exclusively in the dosage form of a tablet intended for oral use.


Q: Does taking Adepal with food change how it is absorbed?

Official administration instructions state that the tablets can be taken without regard to meals. Regulatory information does not typically require specific timing relative to food intake for proper absorption.


Q: What is the purpose of the black box warning on Adepal, if one exists?

The Boxed Warning, a prominent safety notice in official documents, specifically addresses the risk of serious cardiovascular events (such as blood clots, stroke, and heart attack). This risk is substantially increased in women over 35 who smoke, and use is strictly contraindicated in this specific population.


Q: How soon after stopping Adepal can someone switch to a different medication?

Regulatory documents provide instructions for starting Adepal (switching to it), but they do not specify a required waiting period before switching from it to another hormonal method. Non-hormonal contraception may be needed during any transition period.


Q: Does Adepal have any known long-term side effects that appear years later?

Studies have documented a possible increased risk of hepatic adenomas (benign liver tumors) and a possible increased risk of hepatocellular carcinoma (a type of liver cancer) in individuals who use hormonal contraceptives for extended periods, as described in Warnings and Precautions.


Q: Why is Adepal considered a prescription-only medicine?

It is classified as a prescription-only medicine because it is associated with a risk of serious adverse events (like blood clots). This necessitates a professional assessment to ensure the individual does not have high-risk conditions or contraindications that would make its use unsafe.


Q: What is the difference between Adepal and a placebo in studies?

Clinical trials demonstrated that Adepal was effective in preventing pregnancy (e.g., having a very low pregnancy rate) compared to a placebo, which is a substance with no active ingredient.


Q: What is the recommended maximum duration of use for Adepal?

Regulatory information indicates the medication is appropriate for use by females of reproductive potential to prevent pregnancy. The duration is based on the individual’s reproductive needs and medical assessment, and there is no fixed maximum time limit stated in official documents.


Q: How does the effectiveness of Adepal compare across different age groups in studies?

The main clinical studies used to determine effectiveness included women aged 15–40 years. A consistently low pregnancy rate was observed across this population, and the data does not present separate efficacy findings for specific age groups within the approved range.


Q: Does Adepal have an impact on blood sugar levels?

Yes. Regulatory documents note that combined oral contraceptives may decrease glucose tolerance. Regulatory documents state that medical monitoring of blood sugar may be necessary for women with prediabetes or diabetes who use this medication.


Q: Can Adepal be crushed or split if swallowing is difficult?

No. The official administration guidelines require the tablets to be swallowed whole. Crushing or splitting is not permitted because it may interfere with the intended drug release or absorption.

How should Adepal be stored and disposed of?

How to Store and Dispose of Adepal (Levonorgestrel and Ethinyl Estradiol Tablets)

The official regulatory labeling for this combination hormonal contraceptive mandates specific conditions for storage and disposal to ensure stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep the tablets away from heat, moisture, and direct light. Do not allow the product to freeze.
Safety The medication must be kept out of the reach of children.

Disposal Instructions

Disposal of any unused or outdated medication should be done according to the advice of a healthcare professional or local regulations. Environmental protection rules require that the tablets not be flushed down a toilet or sink, and care must be taken to prevent entry into waterways or sewers. If no specific take-back program is available, follow standard FDA guidelines for household disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adepal found in:

A-Z Index: